Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.

Rev Esp Cardiol (Engl Ed)Apr 23, 2026 (epub)
Clinical ResearchCardiology

Sergio Raposeiras-Roubín, Manuel Anguita, Roberto Latini et al.

✦ AI-curated · Sources linked

In 30 seconds

This prespecified analysis from the REBOOT trial evaluated the long-term effects of beta-blockers in invasively managed myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). Among 8,438 patients, beta-blockers were linked to a higher incidence of adverse outcomes in STEMI patients (HR, 1.27) but showed no significant effect in NSTEMI patients. The median follow-up was 3.7 years.

Key findings

  • In STEMI patients, beta-blockers were associated with a higher incidence of the primary endpoint (HR, 1.27; 95%CI, 1.00-1.62).
  • NSTEMI patients assigned to beta-blockers showed no significant effect on the primary endpoint (HR, 0.89; 95%CI, 0.72-1.10).
  • NSTEMI patients with mildly reduced LVEF on beta-blockers experienced significantly fewer events than controls.

Why it matters

The findings suggest that beta-blockers may not provide clear benefits for patients with STEMI and preserved LVEF, while NSTEMI patients with mildly reduced LVEF might benefit, highlighting the need for tailored treatment strategies.

Source

PubMed · PMID 42034335

Published in Rev Esp Cardiol (Engl Ed). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.